Efficacy demonstrating the FDA’s new criteria for "complete cure" outcomes.1
Natroba™ offers substantiated efficacy in treating adult and pediatric (4 years of age and older) scabies infestations.
See the efficacy dataResults from two Phase III, clinical studies based on a single, full-body application of Natroba™.1
When applied on the outer layer of the epidermis, the active compound (spinosad) is absorbed into the stratum corneum (but not beyond) before sloughing off through the natural process of non-pathologic desquamation (over approximately 14 days).1,2
In two phase III, multicenter, randomized, double-blind, vehicle-controlled studies, under patient-directed usage, evaluating a single application of Natroba™ or vehicle in 206 patients, significantly more patients using Natroba™ achieved a complete cure 28 days after treatment compared to vehicle, 69.8% vs. 46.5% (P-value=0.0271) and 83.9% vs. 34.5% (P-value<0.0001), respectively. Patients were less likely to develop new scabies lesions over the 28 days following treatment with Natroba™ than following treatment with vehicle.
Reference(s)
- Natroba Prescribing Information.
- Jackson SM, et. al: Pathobiology of the stratum corneum. West J Med 1993 Mar; 158:279-285).
NAT-SW5-000